Skip to main content
. 2017 Feb 1;7:41892. doi: 10.1038/srep41892

Figure 2. Histopathology associated with AZ31 in moribund mice after TBI and pharmacokinetics of AZ31 and AZD6738 at the time of irradiation.

Figure 2

(A) Photomicrographs of transverse sections of mouse intestine following 9 Gy TBI. Top left: normal small intestinal crypt epithelium following 9 Gy alone (Day 14). Top center: minimal disruption of morphology within the small intestinal crypt epithelium following 75 mg/kg AZD6738 and 9 Gy (Day 14). Top right: disrupted crypt morphology within the small intestine following 100 mg/kg AZ31 and 9 Gy (Day 7). Bottom left: regenerative crypt hyperplasia within the small intestine following 100 mg/kg AZ31 + 75 mg/kg AZ6738 and 9 Gy (Day 6). Bottom center and bottom right: regions of significant atrophy and loss of the crypt epithelium within the small intestine and large intestine, respectively, following AZ31 + AZ6738 and 9 Gy (Day 6). Black bar = 20 μm; red bar = 100 μm. (B) Concentrations of AZ31 and AZD6738 in the plasma, thymus, and small intestinal (GI) mucosa of mice 2 h following a single oral dose of vehicle, 100 mg/kg AZ31, 75 mg/kg AZD6738, or 100 mg/kg AZ31 + 75 mg/kg AZD6738. N = 3 mice per treatment group.